7月1日，Hims & Hers Health盘中上涨5.12%，报37.37美元/股，成交额3.34亿美元。
消息面上，美银证券将Hims & Hers Health目标价从25美元大幅上调至36美元，涨幅达44%，维持中性评级。据FactSet数据，该股当前分析师平均评级为持有，平均目标价为29.27美元。此外，市场关注到雇主正削减GLP-1减重药保险覆盖的趋势，分析师认为这或为Hims & Hers带来新的增长机遇。公司此前已完成对Eucalyptus的收购，将消费健康平台拓展至澳大利亚、加拿大、德国等国际市场，国际化战略持续推进。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.